Abstract 217P
Background
With conditional reprogramming (CR) technique to generate continuous primary cancer cell cultures from bladder cancer patients’ urine samples, we aimed to establish a novel in vitro model by a rapid and non-invasive method to predict clinical response to anti-tumor drugs including immunotherapy and provide drug guidance for patients.
Methods
Patients included were all diagnosed with bladder cancer, among which were 54 high grade and 14 low grade. Urine and tumor samples were collected before therapeutic treatment. The overall success rate was summarized. Whole-exome sequencing (WES) and short tandem repeat (STR) analysis were utilized to confirm the authentication of CR cultures (CRCs). Dose-response measurements were used to generate drug sensitivity scores. Expression of PD-L1 on the cell surface of urine CRCs after IFN-γ treatment is evaluated with flow cytometry.
Results
The overall success rate of establishing urine CRCs was 87.2% (68/78), with 93.1% (54/58) of high grade bladder cancer, 70.0% (14/20) of low grade bladder cancer. Importantly, the in vitro drug sensitivity results of the urine-derived cells exhibited strong consistency (78%) with the clinical responses to treatment, indicating their potential for guiding patient-specific therapeutic strategies. Furthermore, we revealed that IFN-γ-stimulated PD-L1 expression on urine CRCs could predict the prognosis of bladder cancer patients and exhibited predictive value for ICI response in bladder cancer patients with a significant consistency of 88%, highlighting their clinical relevance.
Conclusions
Our study demonstrates the successful establishment of a reliable and patient-specific bladder cancer cell model derived from urine samples which serve to guide anti-tumor drugs and immunotherapeutic interventions. The findings underscore the clinical utility and translational potential of urine-derived cells for personalized bladder cancer management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract